🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 17 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
09/12/2021 43,86 45,88 42,46 42,61 -3,53% 7,79% 738.300
08/12/2021 46,22 47,00 43,63 44,17 -3,35% 7,29% 992.500
07/12/2021 45,00 46,45 44,68 45,70 +4,27% 3,92% 661.200
06/12/2021 44,00 45,21 43,42 43,83 -0,84% 4,07% 643.800
03/12/2021 45,59 45,59 43,53 44,20 -1,76% 4,52% 520.400
02/12/2021 42,95 45,26 42,50 44,99 +4,31% 6,43% 587.000
01/12/2021 43,50 45,84 43,00 43,13 -1,53% 6,53% 588.300
30/11/2021 45,03 45,68 41,63 43,80 -2,93% 8,99% 1.088.200
29/11/2021 47,14 47,28 44,54 45,12 -2,67% 5,81% 611.900
26/11/2021 47,65 48,39 44,02 46,36 -4,33% 9,17% 647.500
24/11/2021 48,06 48,80 47,35 48,46 -0,02% 3,02% 447.100
23/11/2021 47,98 48,78 47,24 48,47 +0,79% 3,21% 539.400
22/11/2021 45,53 49,10 45,00 48,09 +1,14% 9,01% 1.245.700
19/11/2021 44,49 48,03 43,84 47,55 +9,21% 9,42% 1.517.800
18/11/2021 40,56 43,97 39,79 43,54 +17,96% 10,31% 4.452.400
17/11/2021 37,25 37,58 36,46 36,91 -1,10% 3,01% 280.300
16/11/2021 37,83 38,72 37,27 37,32 -1,97% 3,83% 291.100
15/11/2021 38,21 38,47 37,11 38,07 -0,03% 3,56% 399.900
12/11/2021 37,54 38,10 36,71 38,08 +1,71% 3,70% 177.500
11/11/2021 38,91 39,60 37,39 37,44 -3,90% 5,66% 267.200
10/11/2021 38,59 40,33 38,16 38,96 +0,15% 5,64% 907.200
09/11/2021 35,49 39,20 34,85 38,90 +11,97% 12,26% 1.001.800
08/11/2021 36,37 36,37 34,37 34,74 -0,49% 5,49% 660.700
05/11/2021 35,34 36,65 34,15 34,91 -1,36% 7,07% 521.400
04/11/2021 36,39 36,39 34,76 35,39 -2,10% 4,48% 396.100
03/11/2021 33,91 36,64 33,91 36,15 +5,55% 8,05% 403.300
02/11/2021 34,06 34,29 33,44 34,25 +0,44% 2,50% 483.400
01/11/2021 32,92 34,20 32,92 34,10 +1,97% 3,89% 198.700
29/10/2021 33,71 34,26 32,73 33,44 -0,80% 4,55% 223.200
28/10/2021 33,22 33,93 33,22 33,71 +1,87% 2,15% 310.100